Comparative Pharmacology
Head-to-head clinical analysis: LODINE versus NAPROXEN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LODINE versus NAPROXEN SODIUM.
LODINE vs NAPROXEN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibition of prostaglandin synthesis via cyclooxygenase (COX) inhibition, with selectivity for COX-2 over COX-1.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
200 to 400 mg orally every 6 to 8 hours as needed; maximum daily dose 1200 mg.
220-550 mg orally twice daily; maximum 1375 mg/day.
None Documented
None Documented
Terminal elimination half-life approximately 7.5 hours; in elderly or renal impairment, half-life may be prolonged up to 10 hours, requiring dose adjustment
12–17 hours (terminal); allows twice-daily dosing; prolonged in elderly and renal impairment
Primarily renal (60% as metabolites, <1% unchanged); biliary/fecal (30-35%)
Renal: 95% (as unchanged drug, conjugated naproxen, and 6-O-desmethyl naproxen); Fecal: <5%
Category C
Category D/X
NSAID
NSAID